Clinical significance of antinuclear antibody positivity in patients with severe coronavirus disease 2019
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: This study aimed to investigate the clinical characteristics and outcomes of fluorescent antinuclear antibody (FANA)-positive patients admitted for coronavirus disease 2019 (COVID‐19) and identify FANA as a prognostic factor of mortality. Methods: This retrospective study was conducted at a university-affiliated hospital with 1,048 beds from September 2020 to March 2022. The participants were consecutive patients who required oxygenation through a high-flow nasal cannula, non-invasive or mechanical ventilation, or extracorporeal membrane oxygenation, and conducted the FANA test within 48 hours of admission. Results: A total of 132 patients with severe COVID-19 were included in this study, of which 77 (58.3%) had FANA-positive findings (≥ 1:80). FANA-positive patients were older and had higher inflammatory markers and 28-day mortality than FANA- negative patients. In the multivariate Cox proportional hazard regression analysis, FANA-positive findings (hazard ratio [HR], 2.65; 95% confidence interval [CI], 1.04–6.74), age (per 1-year; HR, 1.05; 95% CI, 1.01–1.10), underlying pulmonary disease (HR, 3.16; 95% CI, 0.97–10.26), underlying hypertension (HR, 2.97; 95% CI, 1.28–6.87), and blood urea nitrogen > 20 mg/dL (HR, 3.72; 95% CI, 1.09–12.64) were independent predictors of 28-day mortality. Remdesivir (HR, 0.34; 95% CI, 0.15–0.74) was found to be an independent predictor that reduced mortality. Conclusions: Our findings revealed an autoimmune phenomenon in patients with severe COVID-19, which provides an ancillary rationale for strategies to optimize immunosuppressive therapy. In particular, this study suggests the potential of FANA to predict the outcomes of COVID-19.
Abstract
Background/Aims: This study aimed to investigate the clinical characteristics and outcomes of fluorescent antinuclear antibody (FANA)-positive patients admitted for coronavirus disease 2019 (COVID‐19) and identify FANA as a prognostic factor of mortality. Methods: This retrospective study was conducted at a university-affiliated hospital with 1,048 beds from September 2020 to March 2022. The participants were consecutive patients who required oxygenation through a high-flow nasal cannula, non-invasive or mechanical ventilation, or extracorporeal membrane oxygenation, and conducted the FANA test within 48 hours of admission. Results: A total of 132 patients with severe COVID-19 were included in this study, of which 77 (58.3%) had FANA-positive findings (≥ 1:80). FANA-positive patients were older and had higher inflammatory markers and 28-day mortality than FANA- negative patients. In the multivariate Cox proportional hazard regression analysis, FANA-positive findings (hazard ratio [HR], 2.65; 95% confidence interval [CI], 1.04–6.74), age (per 1-year; HR, 1.05; 95% CI, 1.01–1.10), underlying pulmonary disease (HR, 3.16; 95% CI, 0.97–10.26), underlying hypertension (HR, 2.97; 95% CI, 1.28–6.87), and blood urea nitrogen > 20 mg/dL (HR, 3.72; 95% CI, 1.09–12.64) were independent predictors of 28-day mortality. Remdesivir (HR, 0.34; 95% CI, 0.15–0.74) was found to be an independent predictor that reduced mortality. Conclusions: Our findings revealed an autoimmune phenomenon in patients with severe COVID-19, which provides an ancillary rationale for strategies to optimize immunosuppressive therapy. In particular, this study suggests the potential of FANA to predict the outcomes of COVID-19.
참고문헌 (31)
- Liu Y, "COVID-19 and autoimmune diseases", Curr Opin Rheumatol, 33, pp.155~162 (2021)
- Smatti MK, "Viruses and autoimmunity : a review on the potential interaction and molecular mechanisms", Viruses, 11, pp.762~ (2019)
- Ragab D, "The COVID-19 cytokine storm; what we know so far", Front Immunol, 11, pp.1446~ (2020)
- Baglaenko Y, "The presence of anti-nuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease", Arthritis Res Ther, 20, pp.264~ (2018)
- Esmaeilzadeh A, "Immunobiology and immunotherapy of COVID-19 : a clinically updated overview", J Cell Physiol, 236, pp.2519~2543 (2021)
- "Coronavirus disease 2019 (COVID-19) treatment guidelines" (2020)[URL]
- Charlson M, "Validation of a combined comorbidity index", J Clin Epidemiol, 47, pp.1245~1251 (1994)
- Aringer M, "2019 European League Against Rheumatism", American College of Rheumatology classification criteria for systemic lupus erythematosus, 2019, pp.78, 1151~1159
- Zhou Y, "Clinical and autoimmune characteristics of severe and critical cases of COVID-19", Clin Transl Sci, 13, pp.1077~1086 (2020)
- Sacchi MC, "SARS-CoV-2 infection as a trigger of autoimmune response", Clin Transl Sci, 14, pp.898~907 (2021)
- Lerma LA, "Prevalence of autoantibody responses in acute coronavirus disease 2019(COVID-19)", J Transl Autoimmun, 3, pp.100073~ (2020)
- Pascolini S, "COVID-19 and immunological dysregulation : can autoantibodies be useful?", Clin Transl Sci, 14, pp.502~508 (2021)
- Gagiannis D, "Clinical, serological, and histopathological similarities between severe COVID-19 and acute exacerbation of connective tissue disease-associated interstitial lung disease(CTD-ILD)", Front Immunol, 11, pp.587517~ (2020)
- Chang SH, "Autoantibodies in moderate and critical cases of COVID-19", Clin Transl Sci, 14, pp.1625~1626 (2021)
- Xavier RM, "Antinuclear antibodies in healthy aging people : a prospective study", Mech Ageing Dev, 78, pp.145~154 (1995)
- Nisihara R, "Antinuclear antibodies and rheumatoid factor positivity in healthy elderly adults : a cross-sectional study in 336individuals", J Am Geriatr Soc, 61, pp.2044~2046 (2013)
- Nisihara R, "Anti-nuclear antibodies in patients with breast cancer", Clin Exp Immunol, 193, pp.178~182 (2018)
- Gauderon A, "Antinuclear antibodies with a homogeneous and speckled immunofluorescence pattern are associated with lack of cancer while those with a nucleolar pattern with the presence of cancer", Front Med(Lausanne), 7, pp.165~ (2020)
- Michielsens B, "Diagnostic significance of antinuclear antibodies in neurologic patients", Acta Neurol Scand, 84, pp.102~106 (1991)
- Feghali-Bostwick CA, "Autoantibodies in patients with chronic obstructive pulmonary disease", Am J Respir Crit Care Med, 177, pp.156~163 (2008)
- Ghrairi N, "Antinuclear antibodies in interstitial lung disease : prevalence and clinical significance", Tunis Med, 97, pp.1240~1245 (2019)
- Kim L, "Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019(COVID-19)-associated hospitalization surveillance network(COVID-NET)", Clin Infect Dis, 72, pp.e206~e214 (2021)
- Dessie ZG, "Mortality-related risk factors of COVID-19 : a systematic review and meta-analysis of 42 studies and 423, 117 patients", BMC Infect Dis, 21, pp.855~ (2021)
- Taeschler P, "Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures", Allergy, 77, pp.2415~2430 (2022)
- Peker BO, "Antinuclear antibodies(ANAs)detected by indirect immunofluorescence(IIF)method in acute COVID-19 infection; future roadmap for laboratory diagnosis", J Immunol Methods, 499, pp.113174~ (2021)
- Berger JS, "Prevalence and outcomes of D-dimer elevation in hospitalized patients with COVID-19", Arterioscler Thromb Vasc Biol, 40, pp.2539~2547 (2020)
- Biran N, "Tocilizumab among patients with COVID-19 in the intensive care unit : a multicentre observational study", Lancet Rheumatol, 2, pp.e603~e612 (2020)
- Schiffrin EL, "Hypertension and COVID-19", Am J Hypertens, 33, pp.373~374 (2020)
- Meena P, "COVID-19 and the kidney : a matter of concern", Curr Med Res Pract, 10, pp.165~168 (2020)
- Rubin S, "Characterization of acute kidney injury in critically ill patients with severe coronavirus disease 2019", Clin Kidney J, 13, pp.354~361 (2020)
- Cheng Y, "Kidney disease is associated with in-hospital death of patients with COVID-19", Kidney Int, 97, pp.829~838 (2020)